Abstract Sporadic VIPoma is an exceedingly rare tumor with an annual incidence of 1:10 million people worldwide, yet it is described in approximately 5 % of MEN1 patients. The majority of VIPomas are malignant and radical surgery is the best therapeutic option. A 58-year-old man presented with cardiocirculatory arrest due to ventricular fibrillation. The patient had a 3-month history of epigastric pain with diarrhea. After reanimation, laboratory data revealed severe hypokalemia and hypercalcemia. Further investigations showed hyperparathyroidism, left adrenal adenoma and pituitary microprolactinoma and genetic diagnosis of MEN1 syndrome was made. Abdominal computed tomography revealed a 45 9 30 mm mass of the pancreatic head and two hepatic lesions, which proved to be neuroendocrine after 68 Ga PET and needle biopsy. Vasoactive intestinal peptide (VIP) serum level had increased. Subsequently the patient underwent pylorus-preserving pancreaticoduodenectomy and hepatic resection. Intraoperative VIP returned to normal values. Histopathology confirmed a pancreatic VIPoma metastatic to the liver. The postoperative course was unremarkable and the patient is well with no evidence of disease at a 48 months follow-up. Even in case of anusual presentation, when two or more main clinical findings of MEN1 related tumors are present, unrespectively to the presence of MEN1 mutation, MEN1 syndrome should be suspected. Surgery in MEN1 pancreatic neuroendocrine tumors is indicated both to treat symptoms and to avoid oncological progression even in advanced cases.
Introduction
Pancreatic neuroendocrine tumors (PNETs), formerly referred to as islet cell tumors, arise from ductal pluripotent stem cells of the pancreas and represent 3-4 % of all pancreatic neoplasms, with a prevalence of approximately 1/100,000. PNETs can occur in at least 50 % of patients with multiple endocrine neoplasia type 1 (MEN1) syndrome. In MEN1, up to 30-50 % of PNETs are functioning tumors which manifest specific clinical syndromes. Insulinomas and gastrinomas are the most common, followed by glucagonomas, somatostatinomas and VIPomas [1, 2] . Compared with unaffected MEN1 patients, those with VIPomas carry a fourfold higher risk of death [3] . Pancreatic VIPomas are exceedingly rare, accounting for only 2 % of all PNETs with an annual incidence estimated at 0.1-0.6 per million and are mainly sporadic [4] . In up to 70 % of cases, they behave in a malignant fashion, often manifesting evidence of hepatic metastasis at the time of diagnosis.
Clinical diagnosis of pancreatic VIPoma is straightforward in typical cases presenting the Verner-Morrison triad, first described in 1958 [5] . This syndrome, also known as watery diarrhea, hypokalemia, achlorhydria (WDHA), is caused by overproduction of vasoactive intestinal peptide (VIP) which stimulates fluid and electrolyte secretion in the intestinal epithelium via activation of the cyclic adenosine mono-phosphate pathway [6, 7] . Symptoms of severe electrolyte imbalance include cardiac arrhythmia, neuromuscular deficit, profound shock and cardiovascular collapse [8] [9] [10] . Surgery for complete tumor removal or debulking is the gold standard treatment.
According to NCCN [11] and NANET [12] guidelines, the recommended follow-up strategy for neuroendocrine tumors includes appropriate marker testing and multiphasic computed tomography (CT) or magnetic resonance imaging (MRI) 3-6 months following curative resection and then every 6-12 months thereafter.
We observed a singular presentation of a malignant VIPoma in MEN1 syndrome, responsible for ventricular fibrillation, thus leading a late diagnosis. Even if the oncological stage was advanced, R0 resection of the pancreatic tumor and liver metastases resolved WDHA and the patient remains well with no evidence of disease at 48 months of follow-up.
Case report
A 58-year-old man presented with cardiocirculatory arrest due to ventricular fibrillation. Resuscitation therapy in the emergency room managed to convert the pathologic rhythm. Blood tests revealed severe hypokalemia and hypercalcemia. The patient had been suffering from epigastric pain and diarrhea for 3 months. During the post-acute hospitalization, these dyspeptic symptoms persisted and diarrhea was ascertained to be secretory, since it was voluminous and failed to improve with fasting. Basal VIP serum level was 183 pg/mL (normal value, less than 31 pg/mL). Biochemical assays showed and instrumental investigations confirmed concomitant primary hyperparathyroidism, left adrenal adenoma and pituitary microprolactinoma. Despite a negative family history for endocrine disorders, MEN1 syndrome was hypothesized and the search for a MEN1 gene mutation was performed in our Center. Heterozygous mutation of exon 2 frameshift67ins5 bp of MEN1 was detected.
Abdominal CT revealed a 45 9 30 mm mass of the pancreatic head with an irregular outline and inhomogeneous contrast enhancement, along with two hepatic lesions in segments I and VI. A diagnosis of neuroendocrine tumor was established after 68 Ga PET and needle biopsy. Longacting somatostatin analogs (LAR) and 177Lu-DOTATATE therapy was started.
Seven months later, our Center was consulted regarding the therapy program. The limited reduction in volume of the primary and secondary lesions and the improved general clinical condition of the patient pointed to surgery. Intraoperative ultrasound examination of the pancreas showed a mass in the head but no lesions in the body and tail. Two liver nodules were also demonstrated, one measuring 1 cm in segment 1 (S1) and the other 2 cm in segment 6 (S6). The patient underwent pylorus-preserving pancreaticoduodenectomy with regional lymphadenectomy along the hepatic hilum, hepatic artery and portal lamina. Subsequently, hepatic resection was performed. The caudate lobe was freed from the vena cava by sectioning the Arantius' duct to remove S1. A wedge resection with a large margin was also performed for S6. VIP levels returned to normal 1 h after pancreatic resection (Fig. 1) . Wirsung-jejunostomy was carried out in a double layer of separate stitches. The postoperative course was regular.
Pathologic examination revealed 28 neuroendocrine tumors in the pancreas. The largest nodule, reaching 2.8 cm, had a Ki-67 index lower than 2 % and was immunoreactive for VIP. Vascular invasion was present. Neuroendocrine tumor tissue positive for VIP was also identified in the liver resection specimen (Figs. 2, 3 ). There was no evidence of lymph node involvement. The following year, the patient underwent surgery for hyperparathyroidism, and performed regular clinical, biochemical and instrumental follow up.
Discussion
VIP is a 28-amino acid polypeptide extensively distributed in the gastro-intestinal tract and the brain, with a 1-2 min half-life. Secreted by B-cells of the pancreatic islets in response to ingestion of foods rich in fat, protein or alcohol, Fig. 1 Intraoperative VIP assay. VIP hormone showed a mild increase during the surgical manipulation of the pancreas, and subsequently dropped to about 20 % of the basal value at the end of the operation it enters the portal circulation and is metabolized in the liver. It exerts a relaxant action on the vascular and visceral smooth muscle and also stimulates pancreatic enzyme activity, intestinal secretion of fluids and electrolytes while reducing gastric acidity and gastrin production.
The relevant MEN1 case series published in the literature report a 1 % incidence of VIPomas [13, 14] . The age at diagnosis is usually younger than in sporadic VIPomas. In our case there was no familial history pointing to MEN1 syndrome and MEN1 associated with an advanced neuroendocrine tumor of the pancreas was established at the age of 58. A genetic test performed on his teenage daughter revealed the same MEN1 mutation.
The majority of MEN1-associated VIPomas are malignant [15] . According to the World Health Organization (WHO) 2010 criteria, malignancy in PNETs is graded by assessing the Ki-67 index in the resected specimens [16] . In our case, although the proliferation index was not high, the patient presented with multiple liver metastases and a symptomatic disease. Clinical symptoms arise from excessive production of VIP, a physiologically active hormone. In patients with VIPoma, the most common manifestations are chronic secretory diarrhea, hypokalemia and metabolic acidosis [15, 17] . Watery diarrhea with flushing may persist for years before the diagnosis. Association with acute renal failure has also been reported, since stool output ranges from 1 L to over 10 L a day [18] . Hypokalemia is a universal finding, resulting from fecal loss of potassium and secondary hyperaldosteronism [15] . In a series of 31 patients reported by Peng et al. [17] , all suffered from diarrhea with significant weight loss and dehydration, while 68 % had hypokalemia. Hyperglycemia was also noted in 28 % of patients, which may be the result of hepatic glycogenolysis via VIP [15] . The structural homology between VIP and secretin, glucagon, gastric inhibitory polypeptide (GIP), peptide histidine and isoleucine [19] may account for enhanced secretion of pancreatic juice, inhibition of gastric acid secretion and gallbladder relaxation. Hypercalcemia has been reported in nearly 50 % of patients with the syndrome, probably related to dehydration, electrolyte disturbances secondary to diarrhea, concomitant hyperparathyroidism in MEN1 syndrome or secretion of a calcitrophic peptide by the tumor. Tetany may occur from hypomagnesemia consequent to the diarrhea. Nearly 8 % of patients demonstrate facial flushing. The cause of this patchy erythematous and, sometimes, urticarial flushing is unclear but it has been attributed to VIP or prostaglandins which may be present in the tumor.
Electrolyte imbalance can trigger heart arrhythmia, as reported in a young woman suffering from diarrhea for years before developing paroxysmal atrial fibrillation and who was eventually diagnosed with a pancreatic VIPoma [20] . Ischemic stroke as a presenting symptom of VIPoma has recently been reported in a 13-year old girl [21] . Notably, our case is the first description of potentially lethal ventricular fibrillation due to chronic diarrhea, caused by VIPoma in MEN1, both extremely rare conditions of which the patient was unaware.
As most PNETs appear as hypervascular nodular lesions at contrast-enhanced CT and MRI, cross-sectional imaging findings of pancreatic VIPomas are usually non-specific [22] [23] [24] [25] . However, the role of abdominal CT and/or MRI is pivotal in localizing the lesion and assessing tumor size and anatomic relationships in view of the surgical treatment, which is the standard of care [26] . At times, some PNETs may appear isoattenuating to the surrounding parenchyma and could therefore be overlooked at CT [27] . In addition to conventional imaging modalities, somatostatin-receptor scintigraphy (SRS) has been advocated as the technique of choice to detect and stage pancreatic VIPomas [27, 28] . On abdominal MRI, PNETs may characteristically exhibit low signal intensity on T2-weighted sequence as a result of their collagen content [24] .
The majority of VIPomas are resectable even if diagnosed at an advanced stage, when the tumor is large and involves the surrounding organs or liver metastases have developed. Hepatic metastasis is a frequent finding and should be treated by surgical resection or radiofrequency ablation whenever possible [29] . The long-term results of radical surgery are good with an overall survival similar to nonfunctioning PNETs, approaching 60 % after 5 years and 23 % after 10 years [29] .
Conclusions
Pancreatic VIPomas are rare tumors, accounting for less than 2 % of PNETs, with a reported incidence of 0.1-0.6 per million. The most common symptoms include watery diarrhea, dehydration, weight loss, hypokalemia and achlorhydria. In the context of MEN1 syndrome, VIPoma is one of the slow growing, symptomatic malignancies that should be suspected in cases of chronic diarrhea. These tumors may be difficult to recognize using conventional radiographic studies. VIPomas are often malignant, but it must also be remembered that their hormonal activity can cause sudden death due to electrolyte imbalance and cardiac complications. Surgery remains the mainstay of treatment for MEN1 PNETs and offers the best chance of a long-term biochemical and oncologic cure even in advanced stages of the disease. 
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